Reported Wednesday, HUTCHMED Divests 45% Stake In Shanghai Hutchison Pharmaceuticals For $608M To Focus On Core R&D And Innovative Oncology Therapies

報道稱，HUTCHMED將其在上海和記輝瑞的45%股份出售，金額爲60800萬美元，以便專注於核心研發和創新腫瘤治療。

Benzinga · 01/02 14:11

HUTCHMED continues to deliver on its strategy outlined in November 2022 to create value, prioritize its portfolio and bring innovative medicines to patients globally —
Divestment proceeds to advance HUTCHMED's pipeline and core innovative medicines business —
Focused R&D investment includes HUTCHMED's proprietary antibody-targeted therapy conjugate platform, with first candidates expected to enter clinical trials in the second half of 2025 —

HUTCHMED繼續執行其在2022年11月制定的策略，以創造價值，優先考慮其產品組合，並將創新藥物帶給全球患者——
剝離收益將用於推進HUTCHMED的研發管線和核心創新藥物業務——
聚焦的研發投資包括HUTCHMED自有的抗體靶向治療偶聯平台，首批候選藥物預計將在2025年下半年進入臨牀試驗——

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。更多信息